@article{TAU12807,
author = {Paolo Grassi and Elena Verzoni and Alessia Mennitto and Giuseppe Procopio},
title = {Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice},
journal = {Translational Andrology and Urology},
volume = {5},
number = {6},
year = {2016},
keywords = {},
abstract = {Final results from the randomised phase III METEOR study have been recently published and confirmed the superiority of cabozantinib over everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma (mRCC) who received at least one previous VEGFR tyrosine-kinase inhibitor (TKI) (1).},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/12807}
}